NeuroOne Medical Technologies (NASDAQ:NMTC) Discloses Letter to Shareholders in Recent 8-K Filing

NeuroOne Medical Technologies Corporation, a Delaware-based company specializing in medical technologies, recently disclosed a Letter to Shareholders in a Form 8-K filing with the Securities and Exchange Commission on January 14, 2025. The letter, authored by Dave Rosa, President and Chief Executive Officer of the company, outlines NeuroOne’s accomplishments, ongoing advancements, and strategic plans aimed at generating and delivering value to its stakeholders.

The Letter to Shareholders, accessible on NeuroOne’s investor relations website at https://nmtc1.com/investors, provides insights into the company’s current progress and future initiatives. NeuroOne Medical Technologies emphasized that the information presented in the filing, including the attached Exhibit 99.1, is released in compliance with Regulation FD Disclosure standards and is meant for informative purposes only. It is not intended as formal filings under the Securities Act or the Exchange Act.

Contained within the filing are forward-looking statements, as indicated in Exhibit 99.1 and in previous reports submitted by the company to the Securities and Exchange Commission. While these statements are based on present expectations, NeuroOne warns that actual results may differ significantly from these projections due to various factors.

In addition to the Letter to Shareholders, the 8-K filing includes key financial details and the requisite exhibits, such as the Letter to Shareholders dated January 14, 2025. NeuroOne Medical Technologies Corporation further attached a Cover Page Interactive Data File as part of its compliance with securities regulations.

Concluding the filing, David Rosa, Chief Executive Officer, signed off on behalf of NeuroOne Medical Technologies Corporation as required by the Securities Exchange Act of 1934. This regulatory submission signifies the commitment of the company to adhere to reporting requirements and keep shareholders informed about its strategic direction and financial performance.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read NeuroOne Medical Technologies’s 8K filing here.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders.